Product Information
QC ASPIRIN EC 325 MG TABLET is a generic product labeled by Chain Drug Marketing Association, priced at $0.0222 per EA under NDC 83324005801. Its NADAC has been published 87 times since Feb 5, 2025.
Strength
325 mg/1
Manufacturer
Chain Drug Marketing AssociationNDC
83324005801
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ASPIRINApproval Type
OTC MONOGRAPH DRUG
FDA Application
M013On Market Since
9/27/2024
Pharmacological Classes
Price Statistics
The NADAC for QC ASPIRIN EC 325 MG TABLET has been published 87 times since Feb 5, 2025, and over the history we have for it it has risen 2.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0222 per EA |
|---|---|
| All-time high | $0.0227 (Apr 15, 2026) |
| All-time low | $0.0206 (Jul 23, 2025) |
| 52-week high | $0.0227 |
| 52-week low | $0.0212 |
| Median price | $0.0223 |
| Average price | $0.0221 |
| Largest weekly change | +6.4% (Oct 22, 2025) |
| Weeks tracked | 87 |
| Tracking since | Feb 5, 2025 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 46% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chain Drug Marketing Association manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aspirin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QC ASPIRIN EC 325 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for QC ASPIRIN EC 325 MG TABLET, manufactured by Chain Drug Marketing Association, is $0.0222 per EA (NDC 83324005801), effective Sep 30, 2026.
How has the price of QC ASPIRIN EC 325 MG TABLET changed over time?
Over the history we have for it, the NADAC for QC ASPIRIN EC 325 MG TABLET has risen 2.3%. It has been tracked across 87 weekly CMS publications since Feb 5, 2025.
What are the highest and lowest recorded NADAC prices for QC ASPIRIN EC 325 MG TABLET?
Since Feb 5, 2025, the NADAC for QC ASPIRIN EC 325 MG TABLET has ranged from a low of $0.0206 (Jul 23, 2025) to a high of $0.0227 (Apr 15, 2026), with a median of $0.0223 per EA.
Are there cheaper alternatives to QC ASPIRIN EC 325 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QC ASPIRIN 325 MG TABLET, is $0.0121 per EA — about 46% below QC ASPIRIN EC 325 MG TABLET.
Who manufactures QC ASPIRIN EC 325 MG TABLET?
QC ASPIRIN EC 325 MG TABLET (NDC 83324005801) is labeled by Chain Drug Marketing Association, and CMS classifies it as a generic product.